异体骨板复合自体红骨髓及异体骨粒治疗胫骨骨缺损23例  

Application of Allogeneic Bone Plate Combined with Autologous Red Bone Marrow and Allogeneic Bone Particles in Treatment of Tibial Bone Defect:A Follow-up of 23 Patients

作　　者：徐伟浦 缪建云 丁真奇 练克俭 翟文亮 

机构地区：[1]福建省漳州市解放军第一七五医院,福建漳州363000

出　　处：《中国中医骨伤科杂志》2011年第12期17-18,共2页Chinese Journal of Traditional Medical Traumatology & Orthopedics

基　　金：南京军区"十一五"计划课题资助项目(06MA97)

摘　　要：目的:探讨异体骨板复合自体红骨髓及异体骨粒治疗胫骨骨缺损的临床疗效。方法:2008年6月～2010年9月,共收治创伤性胫骨骨缺损病人23例,其中男15例,女8例;年龄18～58岁,平均34.8岁;左侧10例,右侧13例;胫骨上1/3段占26.1%﹙6例﹚,中1/3段占34.8%(8例),下1/3段占39.1%(9例);全部病例均采用异体骨板复合自体红骨髓及异体骨粒钢板固定。结果:23例患者术后随访14～26个月,平均20.3个月,术后骨缺损愈合良好,平均愈合时间为12.6周。结论:异体骨板复合自体红骨髓及异体骨粒治疗胫骨骨缺损,固定可靠,骨缺损愈合率高,愈合周期短,疗效满意。Objective：To evaluate the effectiveness of allogeneic bone plate combined with autologous red bone marrow and allogeneie bone particles in treatment of tibia1 bone defects. Methods： All 23 patients with traumatic bone defects of tibia were treated from 2008 to 2010, there were 15 males and 8 females, aging 18 58 years （mean 34.8 years）, including 10 ca ses at the left side and 13 at the right side. The proximal one-third segment of tibia shaft defect was 26.1%, middle one third segment was 34.8%, and distal one-third segment was 39.1%. All the patients were treated by allogeneic bone plate combined with autologous red bone marrow and allogeneic bone particles. Results： All patients were followed up for 14 to 26 months, with an average of 20.3 months. The bone defects healing well after surgery, and the average time of bony u nion was 12.6 weeks. According to criterion of Merchan, the results were excellent in 14 cases, good in 5, fair in 2, and no poor case. The excellent and good rate of knee function was 95% （19/21） in one year after operation. Conclusion： It is reliable for allogeneie bone plate combined with autologous red bone marrow and allogeneic bone particles for treatment of traumatic bone defects of tibia, for its advantages of stable fixation, higher bone healing rate, and short healing period.

关 键 词：异体骨板 红骨髓 骨缺损 

分 类 号：R683[医药卫生—骨科学]